Epidemiology of ESBL in hospitals and in the community

Similar documents
PROFESSOR PETER M. HAWKEY

Expert rules. for Gram-negatives

Carbapenemases in Enterobacteriaceae: Prof P. Nordmann Bicêtre hospital, South-Paris Med School

Overcoming the PosESBLities of Enterobacteriaceae Resistance

β-lactamase inhibitors

jmb Research Article Review Semi Kim 1, Ji Youn Sung 2, Hye Hyun Cho 3, Kye Chul Kwon 1, and Sun Hoe Koo 1 *

Expert rules in antimicrobial susceptibility testing: State of the art

Molecular characterisation of CTX-M-type extendedspectrum β-lactamases of Escherichia coli isolated from a Portuguese University Hospital

Determining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing

Academic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE

Enterobacteriaceae with acquired carbapenemases, 2015

Update on CLSI and EUCAST

Public Health Surveillance for Multi Drug Resistant Organisms in Orange County

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014.

breakpoints, cephalosporins, CLSI, Enterobacteriacae, EUCAST, review Clin Microbiol Infect 2008; 14 (Suppl. 1):

Epidemiology of the β-lactamase resistome among Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae in the Chicago region

Imported chicken meat as a potential source of quinolone-resistant Escherichia coli producing extended-spectrum b-lactamases in the UK

A new diagnostic microarray (Check-KPC ESBL) for detection and. identification of extended-spectrum beta-lactamases in highly resistant

Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital

Reporting blood culture results to clinicians: MIC, resistance mechanisms, both?

Emergence of non-kpc carbapenemases: NDM and more

Detection of NDM-1, VIM-1, KPC, OXA-48, and OXA-162 carbapenemases by MALDI- TOF mass spectrometry

Healthcare-associated infections acquired in intensive care units

ESCMID Online Lecture Library. by author

Global Epidemiology of Carbapenem- Resistant Enterobacteriaceae (CRE)

Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Title. Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH

Other antimicrobials of interest in the era of extended-spectrum b-lactamases: fosfomycin, nitrofurantoin and tigecycline

Received 31 January 2011/Returned for modification 2 March 2011/Accepted 15 March 2011

Disclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program

Enterobacteriaceae with acquired carbapenemases, 2016

Infectious Disease Testing. UriSelect 4 Medium. Direct Identification Visibly Reliable

Carbapenem-resistant Enterobacteriaceae (CRE): Coming to a hospital near you?

REVIEW. Hospital, Shrewsbury, Shropshire and 2 Shropshire and Staffordshire Health Protection Unit, Health Protection Agency, UK

Carbapenemase-producing Enterobacteriaceae

GUIDE TO INFECTION CONTROL IN THE HOSPITAL. Carbapenem-resistant Enterobacteriaceae

Lane CR, Kwong JC, Romanes F, Easton M, Cronin K, Waters MJ, Stevens K, Schultz MB, Sherry NL, Tai A, Ballard SA, Seemann T, Stinear T & Howden BP

Clinical significance of extended-spectrum

Outpatient treatment in women with acute pyelonephritis after visiting emergency department

In Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated

Use of Faropenem as an Indicator of Carbapenemase Activity

Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010

Burns outbreaks - the UHB experience

CTX-M: changing the face of ESBLs in Europe

Faecal carriage of extended-spectrum b-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology

The Year in Infection Control

10/4/16. mcr-1. Emerging Resistance Updates. Objectives. National Center for Emerging and Zoonotic Infectious Diseases. Alex Kallen, MD, MPH, FACP

Educational Workshops 2016

HSE co-ordination of UK response to recasting of Euratom directives. Pandemic (H1N1) 2009 influenza: UK situation at 20 August 2009

Healthcare-associated infection: what the impact is and where the burden falls

Received 24 July 2009; returned 28 August 2009; revised 9 October 2009; accepted 17 October 2009

JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1998, p Vol. 36, No. 9. Copyright 1998, American Society for Microbiology. All Rights Reserved.

Guess or get it right?

Evaluation of CHROMagar msupercarba for the detection of carbapenemaseproducing Gram-negative organisms

Sensitivity of Surveillance Testing for Multidrug-Resistant Gram-Negative Bacteria in the

Carbapenem Disks on MacConkey agar as screening methods for the detection of. Carbapenem-Resistant Gram negative rods in stools.

Benefits of the pneumococcal immunisation programme in children in the United Kingdom

Emergence of carbapenemase-producing Enterobacteriaceae in France, 2004 to 2011.

Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia

Rate of Transmission of Extended-Spectrum

Spread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory

Distribution of TEM, SHV and CTX-M Genes among ESBL-producing Enterobacteriaceae isolates in Iran

Clinical Microbiology Newsletter

Perspectives on emerging multidrug resistant organisms in the pediatric setting

Cefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010

High diversity of extended-spectrum b-lactamases among clinical isolates of Enterobacteriaceae from Portugal

Enterobacteriaceae in Bamako, Mali. Laboratoire de Bactériologie-Virologie-Hygiène Hospitalière, CHU Reims, UFR Médecine

The Public Health Benefit of CRE Colonization Testing

ST11 KPC-2 Klebsiella pneumoniae detected in Taiwan

Results and experience of BARN ESBL project. Marina Ivanova and project team Tallinn

Analysis of the common opportunistic pathogens

KPC around the world Maria Virginia Villegas, MD, MSC

J. E. DEGENER, A. C. W. SMIT, M. F. MICHEL H. A. VALKENBURG* AND L. MULLER*

Sepsis Treatment: Early Identification Remains the Key Issue

Rapid identification of emerging resistance in Gram negatives. Prof. Patrice Nordmann

Strain-specific transmission in an outbreak of ESBL-producing Enterobacteriaceae in the hemato-oncology care unit: a cohort study

Extended-Spectrum -Lactamases: a Clinical Update

The revolving door between hospital and community: extended-spectrum beta-lactamaseproducing Escherichia coli in Dublin.

Activity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates

Phenotypic detection of ESBLs and carbapenemases

A Snapshot of Colistin Use in South-East Europe and Particularly in Greece

Diagnosis of CPE: time to throw away those agar plates? Jon Otter, PhD FRCPath Guy s and St. Thomas NHS Foundation Trust / King s College London

Enterobacter aerogenes

Guidelines. 14 Nov Marc Bonten

PREVENTIVE MEDICINE - LABORATORY

ORIGINAL ARTICLE SUSCEPTIBILITY PATTERNS IN GRAM NEGATIVE URINARY ISOLATES TO CIPROFLOXACIN, CO-TRIMOXAZOLE AND NITROFURANTOIN

Antibiotic resistance in bacteria from outpatients

Treatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae

Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis

CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE

Outcomes in UK patients with hospital-acquired bacteraemia and the risk of catheter-associated urinary tract infections

Chapter 2. Detection of ESBL producing Enterobacteriaceae

UTI can affect lower and sometimes both lower and upper urinary tracts. The term cystitis has been used to define the lower UTI infection and is

by author ESCMID Online Lecture Library

Nosocomial infections surveillance in RIPAS Hospital

ALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella

bla TEM bla CTX-M محمد مرتضي اردوني Extended-spectrum beta-lactamases ESBL Avian pathogenic Escherichia coli ESBLs (ESBLs)

#Corresponding author: Pathology Department, Singapore General Hospital, 20 College. Road, Academia, Level 7, Diagnostics Tower, , Singapore

Burns outbreaks - the UHB experience

Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France

Transcription:

Epidemiology of ESBL in hospitals and in the community Dietrich Mack Chair of Medical Microbiology and Infectious Diseases The School of Medicine - University of Wales Swansea P R I F Y S G O L C Y M R U A B E R T A W E U N I V E R S I T Y O F W A L E S S W A N S E A

Outbreak with Klebsiella pneumoniae (SHV-5) Location: Surgical ICU of university hospital with busy liver transplantation unit Patients: 11 Duration: Interventions: Termination: 5 months Contact isolation and single rooms without success Closure of ICU and dedication of a peripheral ward with specific health care personal for ESBLpatients

ESBL-positive strains detected in resistance studies of the Paul-Ehrlich-Gesellschaft 14 Percentage of ESBL-positive 12 10 8 6 4 2 0 1995 1998 2001 2004 E. coli K. pneumoniae K. oytoca http://www.p-e-g.org/ag_resistenz/peg-resistenzstudie%202004.pdf

Molecular types of ESBLs isolated in Hamburg 1998-2001 CTX-M SHV TEM E. coli 2 5 1 K. pneumoniae - 20 1 K. oxytoca 2 1 - All 4 26 2 Stürenburg 2003 Diagn. Microbiol. Infect. Dis. 45:29

ESBL types in enterobacteria of multi-centre study Cologne, Heidelberg, Hamburg 2005 CTX-M SHV TEM E. coli 34 2 3 K. pneumoniae 11 12 - K. oxytoca 4 1 - Enterobacter spp. 6 6 - Proteus mirabilis 3-1 All 58 21 4 Wiegand 2007 J Clin Microbiol 45:1167

ESBL resistance mechanisms among cephalosporin-resistant Enterobacteriaceae in London and South-East England 2004 Species N CTX-M (%) Other ESBL (%) AmpC (%) Escherichia coli 574 291 (50.7) 88 (15.3) 41 (7.1) Klebsiella spp. 243 198 (81.5) 24 (9.9) 1 Enterobacter spp. 201 8 (4.0) 26 (12.9) 90 (44.8) Estimate 2.5% of all E. coli isolates are cephalosporin resistant; 1.1% of all carry CTX-M enzymes 9.7% of all Klebsiella spp. isolates are cephalosporin resistant; 7.6% of all carry CTX-M or other ESBL Potz 2006 JAC 58:320

Emergence of CTX-M-positive Enterobacteriaceae in Austria Percentage of CTX-M-positive strains 90 80 70 60 50 40 30 20 10 0 1998 1999 2000 2001 2002 2003 2004 E. coli Klebsiella spp. Eisner et al 2006 AAC 50:785

Trends in production of ESBLs among Enterobacteriaceae in Italy Inpatients Outpatients 2003 1999 2003 % Total In species Total In species Total In species Escherichia coli 31.9 4.4 10.8 1.2 34.2 1.9 Proteus mirabilis 26.2 25.7 25.7 16.3 39.2 14.8 Providencia stuartii 7.1 36.7 5.3 28.1 10.1 13.8 Klebsiella pneu. 15.1 10.2 37.1 20.0 6.3 2.6 Klebsiella oxytoca 3.4 8.0 4.9 15.1 1.3 3.2 Enterobacter aerog 7.5 17.9 6.0 20.5 5.1 8.3 Luzzaro 2006 JCM 44.1659

Long-term study of ESBL epidemiology in Escherichia coli in Sevilla, Spain Romero 2005 CMI 11:625

Dissemination of CTX-M type ESBL in Enterobacteriaceae in People s Republic of China Munday 2004 Int J Antimicrob Agents 23:175

Characteristics of CTX-M producing E. coli in the Calgary Health Region 2000 to 2005 Pitout 2007 AAC 51:1281

Epidemiology of CTX-M-producing Escherichia coli strains in the UK 2003/2004 Woodford 2004 JAC 54:735

Distribution of episodes of bacteraemia due to ESBL-producing Escherichia coli Rodriguez-Bano 2006 CID 43:1409

Number of ESBL-positive E. coli and Klebsiella spp. bacteraemia cases Number of bacteraemic episodes 18 16 14 12 10 8 6 4 2 0 8.4% 26.5% 0.5% 22.6% 2007 2006 2005 E. coli Klebsiella spp.

Proportion of community-onset and hospitalacquired episodes of ESBL-positive E. coli and Klebsiella spp. bacteraemia Number of ESBL-positive episodes 25 20 15 10 5 0 27.6% 26.6% 22.2% 2007 2006 2005 CA HAI

Risk factors for blood stream infection with ESBL-positive E. coli and Klebsiella spp. OR P value Prior ß-lactam antibiotics 10.86.003 Other antibiotics 7.50.03 Prior admission to ICU 6.0.006 Length of hospital stay > 15 d 2.79.01 Skippen et al. 2006 J Hosp Infect 64:115

Community-onset urinary tract infection caused by CTX-M-positive Escherichia coli in Truro, Cornwall 69 resistant E. coli strains submitted to reference laboratory during 2004-2005 Clonal typing identified CTX-M-group 1 positive outbreak strain different from UK epidemic strain A (CTX-M-15) Cornish outbreak strain caused hospital acquired blood stream infection (patient 1) and mostly community-onset UTI Most patients had hospital contact during the preceding 3 months during period of admission of patient 1 Woodford 2004 JAC 54:735

Independent risk factors for community acquired ESBL-positive urinary tract infections Risk factor OR 95% CI Previous hospitalisation < 3 mo 8.95 3.77 21.25 Antibiotic treatment < 3 mo 3.23 1.76 5.91 Age > 60 yr 2.65 1.45 4.83 Diabetes 2.57 1.20 5.51 Male gender 2.47 1.22 5.01 Klebsiella pneumoniae infection 2.31 1.17 4.54 Previous use of 2nd gen ceph 15.8 1.7 143 Previous use of 3rd gen ceph 10.1 4.2 24.0 Previous use of quinolones 4.1 1.8 9.0 Previous use of penicillin 4.0 1.6 9.0 Colodner 2004 Eur J Clin Microbiol Infect Dis 23:163

Faecal carriage of ESBL positive Enterobacteriaceae England 2004 1.9% Spain 2001/2002 2.1% 7.5% Spain 1991 0.3% 0.7% 2003 5.5% - 11.8% Munday et al. 2004 JAC 54:628 Miro 2005 JAC 56:1152 Valverde 2004 JCM 42:4769

Persistent recovery of ESBL-positive Escherichia coli with CTX-M-14/17 and TEM-35 from farm animals in Wales Liebana et al 2006 JCM 44:1630

Escherichia coli producing CTX-M ESBLs in food animals in Hong Kong Pigs (n=300) 6 (2%) CTX-M-14, CTX-M-3, CTX-M24 Cattle (n=96) 3 (3.1%) CTX-M-13, Pigeons (n=33) 1 (3%) CTX-M-14 Chicken (n=243) 0 Geese (n=32) 0 Ducks (n=30) 0 Duan 2006 Microb Drug Resist 12:145

Isolation of CTX-M ESBL positive Escherichia coli from raw chicken meat sold in the West Midlands, United Kingdom British 1/62 CTX-M-1 Irish 0/3 Brazil 5/10 CTX-M-2 Brazil/Poland/France 3/4 CTX-M-2 Poland 0/4 Netherlands 2/2 CTX-M-2 E/F/DK/D 0/4 Unknown 6/40 CTX-M-2, 8, 14 Total 17/129 (13.2%) Ensor, Warren, et al. 2007 Poster 1025, 17th ECCMID, Munich

Community-acquired bacteraemia with ESBL-carrying Enterobacteriaceae 80 episodes of non-nosocomial bacteraemia 11/80 ESBL: 3 community acquired; 8 health care associated ESBL: 8% E. coli; 25% Klebsiella spp., 20% Proteus mirabilis Admission from nursing home risk factor (OR 4.76, P=.001) 10.8% patients admission faecal carriage of ESBL organism 15.4% of colonised patients developed bacteraemia due to CAZ-resistant organism during hospitalisation (OR 38.9; P<.001) 73% of community-acquired organisms carried CTX-M ESBLs Ben-Ami 2006 CID 42:925

Distribution of ESBL-positive Escherichia coli in long-term care facilities in Belfast area A. Loughrey, P. Rooney, M. O'Leary, M. McCalmont, M. Warner, E. Karisik, P. Donaghy, B. Smyth, N. Woodford, D. Livermore 2007 Poster 17th ECCMID Munich

Conclusions CTX-M ESBL predominate in many parts of the world Infections with ESBL-carrying Enterobacteriaceae tend to originate increasingly in the community Carriage rate for ESBL-positive Enterobacteriaceae may be substantial, but more data needed Colonisation of nursing home residents appears to exceptionally high in some places ESBL-positive Enterobacteriaceae are found in food animals

Collaborators Angharad P. Davies Llinos Harris Caron Jones Naledi Bome Irith Wiegand Enno Stürenburg Harald Seifert Heinrich K. Geiss Khalid El-Bouri Ann M. Lewis Nidhika Berry EU ESF Fund Wyeth